Department of Health Sciences, National Natural Science Foundation of China, Beijing, 100085, PR China; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, PR China.
Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100020, PR China.
Cancer Lett. 2023 Oct 10;574:216334. doi: 10.1016/j.canlet.2023.216334. Epub 2023 Aug 11.
Liver cancer is among the leading causes of cancer-related death worldwide and China accounts for nearly half of the global burden of liver cancer. Effective interventions such as hepatitis vaccinations, new blood tests and imaging tests significantly decreased the incidence worldwide, especially in China. Unraveling the systemic and molecular mechanisms of liver cancer would contribute to develop more effective therapies to prolong the 5 year survival of the patients. The Chinese funding agencies have been paying high attention to the basic and translational research of liver cancer. Over the last decade, the National Natural Science Foundation of China (NSFC) initiated a panel of research programs which supported liver cancer research in multiple directions. Besides, great progress has been made in basic and clinical research, platform construction and drug development in the field of liver cancer. In this article, we summarized the funding landscape, research progress, cooperation among countries and institutions, and drug discovery in China, with an attempt to compare the status and outcome with our peers globally.
肝癌是全球癌症相关死亡的主要原因之一，中国占全球肝癌负担的近一半。有效的干预措施，如肝炎疫苗接种、新的血液检测和成像检测，显著降低了全球的发病率，特别是在中国。揭示肝癌的系统和分子机制将有助于开发更有效的治疗方法，延长患者的 5 年生存率。中国的资助机构一直高度重视肝癌的基础和转化研究。在过去的十年中，中国国家自然科学基金委员会（NSFC）启动了一系列研究计划，从多个方向支持肝癌研究。此外，在肝癌基础和临床研究、平台建设和药物开发方面也取得了重大进展。本文总结了中国肝癌研究的资助情况、研究进展、国家和机构间的合作以及药物研发情况，试图与全球同行进行比较，了解其现状和成果。
